赛托生物(300583) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥206,998,521.26, a decrease of 27.75% year-on-year[9] - Net profit attributable to shareholders was ¥19,791,862.76, down 33.25% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,181,319.45, a decrease of 17.35% year-on-year[9] - Basic earnings per share for the reporting period was ¥0.1851, down 32.59% compared to the same period last year[9] - The weighted average return on net assets was 1.07%, a decrease of 0.52% compared to the previous year[9] - The company reported a decrease in net profit guidance for the upcoming quarter, reflecting ongoing market challenges[9] - Total operating revenue for Q3 2019 was CNY 206,998,521.26, a decrease of 27.8% compared to CNY 286,508,705.48 in the same period last year[38] - Net profit for Q3 2019 was CNY 19,292,580.06, representing a decline of 35.6% from CNY 29,956,040.16 in Q3 2018[39] - The company reported a total profit of ¥96,763,935, down from ¥121,882,847, reflecting a decrease of about 20.6%[47] - The company’s total comprehensive income for the current period is ¥82,433,334, compared to ¥100,408,496 in the previous period, indicating a decrease of about 17.9%[49] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥80,725,716.51, an increase of 129.60%[9] - The net cash flow from operating activities improved by 128.42%, reaching ¥80,725,716.51, due to reduced raw material purchases and improved payment methods[20] - Cash flow from operating activities generated a net amount of ¥80.73 million, a significant improvement from a net outflow of ¥284.05 million in the previous period[54] - Net cash flow from operating activities was CNY 162,837,035.03, compared to a negative CNY 214,971,814.47 in the same period last year[56] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,956,164,093.12, an increase of 5.39% compared to the end of the previous year[9] - Total liabilities reached CNY 1,037,690,799.67, up from CNY 844,347,122.68, indicating an increase of approximately 23%[30] - The company's equity attributable to shareholders decreased to CNY 1,865,677,819.54 from CNY 1,907,145,232.71, a decline of about 2.2%[31] - Total assets increased to CNY 2,790,749,742.23, compared to CNY 2,542,968,929.67 at the end of the previous year[36] - Total liabilities rose to CNY 842,659,454.54, up from CNY 672,039,386.23 year-on-year[35] - Total liabilities amounted to CNY 844,347,122.68, with non-current liabilities totaling CNY 98,499,305.89[63] Expenses - Sales expenses decreased by 32.65% to ¥5,866,523.51, due to optimized personnel structure and reduced exhibition costs[20] - Financial expenses rose by 60.78% to ¥24,685,032.95, driven by increased bank loans and financing costs[20] - The company reported a decrease in management expenses to CNY 20,601,473.41 from CNY 12,890,868.64, reflecting a 59.9% increase year-on-year[38] - The company’s management expenses increased to ¥52,154,573 from ¥43,031,227, representing an increase of approximately 21.8%[47] Investments - The investment cash flow net amount decreased by 49.33% to -¥113,018,451.77, mainly due to an increase in the net amount recovered from short-term financial products[20] - The company reported a significant increase in cash received from other investment activities, totaling CNY 623,177,017.88 compared to CNY 228,000,000.00 last year[56] Shareholder Information - The top shareholder, Shandong Runxin Investment Co., Ltd., holds 36.87% of the shares, with a total of 39,802,720 shares pledged[13] - The company did not execute any cash dividend policy during the reporting period[23] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[24] Other Financial Metrics - Other income surged by 280.09% to ¥3,280,882.50, primarily from increased government subsidies related to daily operations[20] - Research and development expenses for Q3 2019 were CNY 11,711,583.82, an increase of 84.5% compared to CNY 6,355,781.34 in the same period last year[38] - Research and development expenses increased to ¥9,007,746 from ¥5,681,461, marking a rise of about 58.5%[43]